A recently published nationwide retrospective cohort study in the Netherlands reported an increase in the national testing rate for KRAS mutations in non-squamous NSCLC, from 70% in 2013 to 82% in 2017; the development of new technologies such as NGS certainly favored this promising tendency [20]. Here, KRAS is linked to non-small cell lung carcinoma.